WRAL Tech Wire

How long before Salix Pharmaceuticals hits $1B?

After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.

FTC tentatively approves Talecris-Grifols merger

Talecris Biotherapeutics' $4 billion merger with Grifols SA of Spain has won tentative approval from U.S. antitrust regulators.

FTC may challenge Grifols buy of Talecris

Sources close to the deal say U.S. antitrust regulators may challenge Spanish healthcare firm Grifols' planned buy of Talecris Biotheraputics.

Talecris stockholders agree to Grifols merger

Talecris shareholders vote in RTP on Monday to proceed with proposed merger with Grifols, but still await final approval by U.S. Federal Trade Commission.

Talecris Biotherapeutics sells to Spanish firm for $4 billion

Talecrids shares surge 26 percent after the news. The RTP-based manufacturer of plasma-based drug therapies agrees to be acquired by Spainish healthcare giant Grifols SA.

Talecris

Talecris execs 'fully expect' Clayton expansion to proceed

The blood plasma thereapeutics firm says its $4 billion acquisition by a Spanish firm is about “growth and creating a global platform.” However, government approval may not come quickly.

Talecris readies for long-delayed IPO

Talecris Biotherapeutics Inc. is expected to go public this week, offering 28.9 million shares for $18 to $20 apiece.

Talecris launches initial public offering 'road show', aiming for nearly $900 million

RTP-based maker of plasma-based therapeutics withdrew a $1 billion IPO in 2007. A $3.1 billion merger with Australian rival fell through earlier this summer. Talecris plans to trade on Nasdaq under symbol TLCR.

Talecris looks to raise some $900 million in stock offering

RTP-based firm, which is world’s third largest manufacturer of plasma-based therapies, seeks to go public. In June, its $3.1 billion merger with Australian rival CSL fell through when challenged by U.S. FTC.